The recent coronavirus vaccine race has been fraught with setbacks. Both Astra Zeneca and Johnson & Johnson recently halted their respective COVID-19 vaccine programs due to a participant’s unexplained reactions.There appears to be no such trouble right now for a fellow pharma heavyweight seeking to be first to market with a viable solution.On Friday, Pfizer (PFE) said that based on interim data, by the end of October it hopes to find out whether its COVID-19 vaccine – developed in collaboration with BioNTech (BNTX) – is effective or not.Moreover, by mid-November it hopes to have enough safety and manufacturing data available …read more
Source:: Yahoo Finance
